Daily BriefsMost Read

Most Read: HKEX, Pasona Group, Korea Stock Exchange KOSPI 200, Eoflow , Asahi Group Holdings, Alibaba Group Holding , Steadfast and more

In today’s briefing:

  • FRTIB Switches Benchmarks: +EM/-DM; US$56bn Trade as Asia EM Benefits & HK Loses Out
  • Pasona: The Wrong Price
  • New Phase in Korean Short Selling: Immediate Impact of MM and LP Short Selling Ban
  • EOFlow Craters. Medtronic Stays Mum
  • Asahi Group Holdings (2502) Offering – Some Index Demand But Needs Lots of Active Long-Onlies
  • Asahi Group Placement – Relatively Small One when Compared to Previous Large JP Secondary Selldowns
  • Alibaba (9988 HK): 2Q24, Higher Margin Means Smooth Reorganization, Buy
  • Steadfast Group Placement – While Accretion Here Is Limited, Past Deals Have Done Well
  • Asahi Group (2502 JP): Big Placement with Limited Index Buying; Timing Is Key
  • Key Points We Should Know Regarding the Current Status of EOFlow


FRTIB Switches Benchmarks: +EM/-DM; US$56bn Trade as Asia EM Benefits & HK Loses Out

By Brian Freitas

  • The FRTIB has decided to switch its benchmark for the International Stock Index Investment Fund from the EAFE Index to the ACWI IMI ex-USA ex-China ex-Hong Kong Index.
  • With around US$68bn invested in the I Fund, this will set off churn among the constituent stocks in 2024. One-way trade is around US$28bn with DM outflows and EM inflows.
  • The benchmark shift could be done over a 4 month period with higher trading during periods where liquidity opportunities arise.

Pasona: The Wrong Price

By Travis Lundy

  • As discussed here in a piece about the Partial Tender Offer, Pasona Group (2168) has agreed to sell its controlling stake in Benefit One (2412) to M3 (2413).
  • That will leave Pasona Group with a fair chunk of cash and possibly a residual stake in Benefit One, depending on the results.
  • Though we don’t know what the future holds, Pasona now is the wrong price for its future. 

New Phase in Korean Short Selling: Immediate Impact of MM and LP Short Selling Ban

By Sanghyun Park

  • There is a prevailing sentiment in the local market that short selling by market makers (MM) and liquidity providers (LP) will effectively be prohibited very shortly.
  • The widening of the futures basis extends the influence of futures on the spot market prices. This is precisely where trading opportunities that we should be keenly observing may arise.
  • It also leads to a significant widening of ETF tracking errors due to the direct sell-off of underlying shares. We must capitalize on extreme spreads in ETFs.

EOFlow Craters. Medtronic Stays Mum

By David Blennerhassett

  • Five weeks after shares were suspended, EOFlow (294090 KS) shares resumed trading this morning, the 16 November. Wording is sparse on the resumption.
  • One small consolation was that EOFlow may benefit from the temporary ban on short selling. Irrespective, shares have declined ~27% at the open, as I type.  
  • Elsewhere, Medtronic Plc (MDT US) provides no guidance. The only other news of note are the various court filings in the District Court of Massachusetts.

Asahi Group Holdings (2502) Offering – Some Index Demand But Needs Lots of Active Long-Onlies

By Travis Lundy

  • Asahi Group Holdings (2502 JP) today announced a collection of 10 shareholders (mostly financial institutions) would sell a total of 33.48mm shares (6.6% of shares out) in Asahi Group. 
  • This will become more of a thing going forward. Cross-holders “want” to unwind. And in many cases, the cross-held want to buy back stock (reduce E, raise ROE).
  • This deal is “good” in that it clears out a lot of the bank cross-holders in one fell swoop. But there are more crossholders behind.

Asahi Group Placement – Relatively Small One when Compared to Previous Large JP Secondary Selldowns

By Clarence Chu

  • A group of shareholders are looking to raise US$1.3bn (JPY197.8bn) by selling their respective stakes in Asahi Group Holdings (2502 JP) via an extended secondary follow-on.
  • The deal would represent 23 days of Asahi’s three month ADV. Its latest extended large primary deal has done very well.
  • While the deal isn’t particularly well flagged, it is an extended one allowing the market to price in the impact of the share sale. 

Alibaba (9988 HK): 2Q24, Higher Margin Means Smooth Reorganization, Buy

By Ming Lu

  • Alibaba’s operating margin rose to 15% in 2Q24 versus 12% in 2Q23.
  • Every expense as percentage of total revenue decreased and EBITDA of every business line increased.
  • We believe the reorganization is going smoothly and the stock has an upside of 82%. Buy.

Steadfast Group Placement – While Accretion Here Is Limited, Past Deals Have Done Well

By Clarence Chu

  • Steadfast (SDF AU) is looking to raise around A$280m (US$180m) to fund the acquisition of Sure Insurance, and provide headroom for potentially additional acquisitions over the year.
  • SDF has undertaken a number of capital raises in the past to similarly fund its active acquisition strategy. Overall, the firm’s past deal record has been strong.
  • In this note, we will talk about the acquisition and run the deal through our ECM framework.

Asahi Group (2502 JP): Big Placement with Limited Index Buying; Timing Is Key

By Brian Freitas

  • Nine shareholders are looking to sell 33.48m shares of Asahi Group Holdings (2502 JP). That is US$1.28bn, 24x ADV and 6.6% of shares outstanding.
  • Given the recent run up in the stock, there could be downside over the next couple of weeks ahead of the pricing date.
  • There will be buying from global trackers but nothing from TOPIX trackers, so not a lot of stock will be mopped up. Passive buying before settlement could create a squeeze.

Key Points We Should Know Regarding the Current Status of EOFlow

By Sanghyun Park

  • It can be considered that the suspension of EOFlow’s trading and, furthermore, the risk of delisting have been completely eliminated at this point.
  • EOFlow emphasizes the possibility of circumventing sales of EOPatch by supplying EOPump to a JV in China. The key factors that initially sparked Medtronic’s interest in EOFlow are still valid.
  • If CEO Kim fails to repay a stock collateral loan of ₩20B or secure additional loans, approximately 4% of the total issued shares could be sold in the market.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars